Status:
COMPLETED
Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
Lead Sponsor:
University of L'Aquila
Conditions:
Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Following radical prostatectomy (RP), about 20% to 40% of the patients with prostate cancer (PCa) exhibit pathological parameters which are associated with a high risk of disease recurrence. The ratio...
Eligibility Criteria
Inclusion
- Patients with cT2-T3a prostate cancer
Exclusion
- Men\>75 years
- Men\<18 years
- Prior hormonal therapy
- Prior radiation or chemotherapy
- Prior investigational agents
- Life expectancy \> 10 years
- Prior malignancy within the last five years
- Any other serious medical or psychiatric condition
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00421694
Last Update
October 8 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of L'Aquila
L’Aquila, Abruzzo, Italy, 67100